Category

BioTalk

Alex Philippidis, Genetic Engineering and Biotechnology News Senior News Editor, Guests on BioTalk

By | BioTalk, News | No Comments

Alex Philippidis joins Rich Bendis on BioTalk to discuss the BioHealth Capital Region from a National viewpoint, other Hubs, and how the industry has adapted in the age of COVID-19.

Alex specializes in biopharma business news and industry issues for GEN. He joined GEN in 2011 after four years at GenomeWeb, where he covered research institutes and spent three years following biotech economic development as editor of the weekly newsletter BioRegion News. Alex reports a variety of news stories for GEN and Clinical OMICs and compiles the popular A-Lists series.

Alex previously worked for more than 20 years for various newspapers covering business, science, the Navy, and general-interest news. He has been interviewed and quoted by news outlets, including the New York Times and the BBC. He enjoys solving crossword puzzles, watching classic TV game shows, and traveling with his family.

Listen now on Google https://bit.ly/2Zj6Jd8, Apple https://apple.co/3eMbNNu, Spotify https://spoti.fi/389Jk1Chttps://bit.ly/38d32K3, and YouTube (audio) https://bit.ly/31tr16m.

Click here to view the transcript.

Charles Andres and Christian Barrow join BioTalk to discuss investing, growth and the BioHealth Capital Region during COVID-19

By | BioTalk, News | No Comments

Charles Andres, Ph.D., RAC, Associate at Wilson Sonsini Goodrich & Rosati, and Christian Barrow, Executive Director, Life Sciences Banking at JP Morgan, join Rich Bendis for a Virtual BioTalk

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Christian Barrow is a senior banker with J. P. Morgan commercial bank. Chris joined J.P. Morgan in 2012 in the Philadelphia office, where he and his team focus on providing financial solutions to life sciences companies located in the Mid-Atlantic – Delaware, Pennsylvania, and Maryland. Chris has over 25 years of experience in the financial services industry with roles that have spanned from public accounting to banking.

Chris’ current job is to help life science companies in biotech, specialty pharmaceutical, specialty pharmacy, medical device, med-tech, medical diagnostics, and contract research organizations, gain access to JPMorgan’s well-known healthcare commercial and investment banking resources.

Prior to his current role, Chris started his career with EY (inactive CA and CPA licenses). He subsequently served as a senior banker for Bank of America. In this capacity, he was responsible for origination and structuring of debt products to general industry companies located in Pennsylvania.

Chris holds a bachelor’s degree in Biology and a graduate diploma in Accounting both from McGill University. He currently resides in Doylestown, Pennsylvania with his wife and two children.

Listen now via Apple https://apple.co/2Z4yyWC, Google https://bit.ly/2AYElou, Spotify https://spoti.fi/3eqnfhR, TuneIn https://bit.ly/3fM8N3R, and audio via YouTube https://bit.ly/3fMmvnj

Emergent BioSolutions Executive Vice President, Manufacturing and Technical Operations, Sean Kirk Guests on BioTalk

By | BioTalk, News | No Comments

Sean M. Kirk, Executive Vice President, Manufacturing and Technical Operations at Emergent BioSolutions joins Rich Bendis to discuss the COVID-19 Health Crisis, Emergent’s Capabilities in Manufacturing in the BioHealth Capital Region and Beyond

 

Listen now via Apple Podcasts (https://apple.co/3aDYSLz), Google Podcasts (https://bit.ly/2Uzh5o6), Spotify (https://spoti.fi/3bIzTqt), and TuneIn (https://bit.ly/3bOKSyV)

 

Mr. Kirk joined Emergent BioSolutions in 2003 and has served as executive vice president, manufacturing and technical operations since April 2019. Prior to this position, Mr. Kirk has held various senior leadership roles including senior vice president, manufacturing operations and contract development and manufacturing operations (CDMO) business unit lead from April 2017 to March 2019, senior vice president, biodefense operations from November 2015 to March 2017, senior vice president, biosciences operations from February 2014 to November 2015 and senior vice president, biodefense vaccines and therapeutics development from March 2012 to February 2014. Mr. Kirk also served in multiple roles of increasing responsibility at Emergent’s manufacturing operations site in Lansing, Michigan.

 

Before joining Emergent, Mr. Kirk worked at Merial, a multinational animal health company, serving in various positions from 1996 to 2001. Mr. Kirk received both an M.B.A. and B.S. in Microbiology from the University of Georgia.

Stewart L. Edelstein, Ph.D., Executive Director of the Universities at Shady Grove, Joins Rich Bendis on BioTalk

By | BioTalk, News | No Comments

Executive Director of the Universities at Shady Grove, Stewart L. Edelstein, Ph.D., joins BioTalk to discuss his career, USG, and its role in the BioHealth Capital Region

Dr. Stewart Edelstein joined the Universities at Shady Grove (USG) as Executive Director in 2002 and in 2007 was named to the dual title of Associate Vice Chancellor for Academic Affairs for the University System of Maryland (USM).

USG is a regional campus of USM that offers both undergraduate and graduate degree programs from nine partner universities. During Dr. Edelstein’s tenure, USG expanded its number of participating universities, as well as the breadth and depth of its academic programs, and enrollment has grown significantly, to more than 3,000 students. The campus’s capacity for future enrollment growth has doubled with the recent opening of a new Biomedical Sciences and Engineering Education Facility, which is expanding degree and certification offerings in healthcare, engineering, biosciences, computer science and other areas.

Under Dr. Edelstein’s leadership, USG has collaborated with Montgomery College and Montgomery County Public Schools (MCPS) to better articulate curriculum planning and degree completion initiatives within the county. An important partnership is a series of 2+2+2 programs – together with MCPS and MC – to create education and career pathways in professional fields. These initiatives place special emphasis on strengthening the pipeline for underrepresented and first-generation college student populations.

Dr. Edelstein serves on the Montgomery County Chamber of Commerce’s board of directors and as co-chair of its Economic Development Committee. He is on the board of Identity, WorkSource Montgomery, and Montgomery Moving Forward, and on the Maryland Cybersecurity Council. He served as a member of the Montgomery County Bioscience Task Force, the Montgomery County Smart Growth Initiative, and the Montgomery County Life Sciences Advisory Committee. He has been honored for his many contributions to the community by the Montgomery County Chamber, the Montgomery County Board of Education, and by the County Executive’s Hispanic Gala.

Prior to arriving at USG, Dr. Edelstein enjoyed a 25-year career at the University of Maryland, College Park, where he ultimately served as Senior Associate Dean of the College of Behavioral and Social Sciences. Dr. Edelstein received his bachelor’s degree from the State University of New York at Buffalo and his master’s degree and Ph.D. from the University of California at Berkeley.

Listen now on Google http://bit.ly/2QjAvL4, Apple https://apple.co/2U7Mexv, Spotify https://spoti.fi/38Rge5R, and TuneIn http://bit.ly/2wee42W

Click here to view the transcript.

Chris Frew, Founder of BioBuzz and Workforce Genetics, Joins Rich Bendis on BioTalk

By | BioTalk, News | No Comments

BioBuzz and Workforce Genetics Founder, Chris Frew, Joins BioTalk to discuss building two organizations, talent acquisition, and his role in the BioHealth Capital Region

Chris is the Founder and CEO of Workforce Genetics, LLC (WGx), and BioBuzz Media to foster highly engaging experiences that connect people and companies across biohealth ecosystems. His insights into talent attraction, employer branding, and marketing have helped top companies to tackle their most pressing challenges in the new talent economy. Previously as Vice President at Breezio, a leading innovator in cloud-based online communities, he lead the development of the new Internship Network of Maryland (inMD) platform that was approved by Gov. Hogan in 2017. As Vice President of Tech USA’s Scientific Division Chris founded and ran a national staffing division operating at $23M annually when he left in 2015. Chris is passionate about impacting others, especially his family and his team, and helping to foster a strong community within the BioHealth Capital Region. He is a Maryland native and a graduate of Towson University. Learn more at https://www.workforcegenetics.com/ and http://biobuzz.io/

Listen now on Apple https://apple.co/39DicIl, Google http://bit.ly/2Q0e1id, Spotify https://spoti.fi/3aDIOZL, and TuneIn http://bit.ly/2TJr4Fu.

Click Here to Download the Transcript 

BHI Managing Director, Economic Development, Judy Costello joins BioTalk to discuss her Career, BioHealth Innovation, and the BioHealth Capital Region

By | BioTalk, News | No Comments

Judy Costello is the Managing Director of Economic Development for BioHealth Innovation, Inc. (BHI). A longtime supporter of the region’s entrepreneur and start-up communities, Judy Costello joined BioHealth Innovation in August 2017. Prior to that she served as Director of the Maryland Department of Commerce’s Office of BioHealth and Life Sciences and Deputy Director of the department’s BioMaryland Center. She previously worked for fifteen years for the Business Alliance organizing venture pitch forums, entrepreneur bootcamps, tech transfer showcases, educational seminars, and other programs connecting entrepreneurs, faculty innovators, students, and industry leaders in Maryland, DC and Virginia with each other and with those providing funding and other resources to young companies.

Listen now on Apple (https://apple.co/32oVlh6), Google (http://bit.ly/32kjUvx), Spotify (https://spoti.fi/38VP3HZ), and TuneIn (http://bit.ly/32mOuo8)

Click here to download the PDF Transcript

Chuck Morton, Partner, Venable, LLP, guests on BioTalk

By | BioTalk, News | No Comments

Chuck Morton, Partner, Venable, LLP, joins BioTalk host Rich Bendis to discuss the local entrepreneurial and business ecosystem, regionalism, and the BioHealth Capital Region

Chuck Morton is co-chair of Venable’s Corporate Group. Chuck is recognized for his abilities in guiding financing, mergers and acquisitions (M&A), and other transactions involving middle-market companies. Chuck assists lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses, primarily in the healthcare, technology, and consumer products industries. He regularly acts on behalf of private equity groups and banks. Chuck currently serves as the Secretary on the BioHealth Innovation Board of Directors.

Listen now on Apple Podcasts https://apple.co/2QwoEIl, Google Podcasts http://bit.ly/33sWjJc, and TuneIn http://bit.ly/2M60Wmx

BioTalk Host Rich Bendis Guests on The ZIDDANDFIXX Show: Angels Talk Podcast

By | BioTalk, News | No Comments

Usually BioHealth Founder and CEO, Rich Bendis, is the host asking questions of his guests on the BioTalk Podcast. However, Rich was recently a guest on the “The ZIDDANDFIXX Show: Angels Talk” Podcast for their 26th Episode titled “The Golden Triangle: DC joins San Francisco and Boston.” They discussed Venture Capital, Angel Investment, and the BioHealth Capital Region.

Ziad Moukheiber of Boston Harbor Angels (East Coast), and Faz Bashi (West Coast) of Life Science Angels have a good time chatting about Angel Investing, Entrepreneurship, Restaurants, Politics with good friends and always with great humor and lots of laughter!

Click the link above to listen!

 

BioTalk from the BioHealth Capital Region Investor Forum – Super Angel Investor, Dr. Faz Bashi, M.D.

By | BioTalk, News | No Comments

Super Angel Investor, Faz Bashi, MD, guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about his background in Immunology/Virology, Venture Investing, and coming to the BioHealth Capital Region.

Listen on Google Podcasts bit.ly/2qR2cRE, Apple Podcasts apple.co/32Ta8A3, and TuneIn bit.ly/2Nip5VJ.

Dr. Faz Bashi, M.D., has a background in Immunology and Virology from UCSF. Faz is the Chair of the Medical Device Screening Committee of Life Science Angels and is an active member of the LSA screening committee for Biotechnology and Pharmaceuticals. He is also the Chair of the Angel Capital Association’s Life Sciences Syndication Group, is a member of the Berkeley Angel Network, and was one of the founding members of Healthtech Capital, where he served two years on the Board of Directors.

He is an adjunct professor in the Integrative Health Studies program at the California Institute of Integral Studies. Faz is an active advisor to the UCSF Clinical and Translational Science Institute. He had worked previously at San Mateo Medical Center developing and implementing special clinical projects targeted towards helping those who are under-served, which included projects focused on TeleDermatology, Diabetic Retinopathy, Screening, and advancements in electronic medical records. Faz is an active consultant to Coleman Associates as a Deep Dive expert, and he coaches public health clinics and safety net organizations on improving their workflow processes. He currently serves as an External Advisory Board Member at The Johns Hopkins University’s Center for Bioengineering Innovation and Design.

BioTalk from the BioHealth Capital Region Investor Forum – Cartesian Therapeutics’ President & CEO Murat Kalayoglu, MD, Ph.D.

By | BioTalk, News | No Comments

Cartesian Therapeutics’ President & CEO Murat Kalayoglu, MD, Ph.D., guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about developing novel cell and gene therapies, building his company in the region, and also being an investor.

Listen now on Apple Podcasts https://apple.co/2pNSKhr, Google Podcasts http://bit.ly/2qCatIU, and TuneIn http://bit.ly/2Wb14DP

Dr. Kalayoglu is co-founder and CEO of Cartesian Therapeutics, a fully-integrated, clinical-stage biopharmaceutical company developing novel cell and gene therapies to treat cancer and autoimmune diseases. Before Cartesian, he was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan (NYSE:AGN). Prior to Topokine, he was co-founder and COO of HealthHonors Corporation, which he led from concept to commercialization, followed by a successful sale to Healthways (NASDAQ:HWAY). Dr. Kalayoglu is a board-certified ophthalmologist who completed his residency and research fellowship at Harvard, MD/Ph.D. in immunology at the University of Wisconsin-Madison, and MBA from the MIT Sloan School of Management.

Founded in 2016, Cartesian is a fully-integrated, clinical-stage biopharmaceutical company developing novel cell and gene therapies to treat cancer and autoimmune diseases. All of the company’s products are manufactured internally at the company’s wholly-owned cGMP manufacturing facility in Gaithersburg, MD. Cartesian has three programs in clinical development. The lead product, Descartes-08, is a CD8+ CAR T-cell therapy with a defined and predictable half-life, enabling repeat dosing to maximize potency while minimizing risk of toxicity. Descartes-08 is currently in Phase I/II clinical trials to treat patients with multiple myeloma.

Join our Mailing List